Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Australia ETF (EWA) vs Novo Nordisk A/S (NVO) Price & Performance

iShares MSCI Australia ETFTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

iShares MSCI Australia ETF vs Novo Nordisk A/S — how do they compare? iShares MSCI Australia ETF trades at $29.87, while Novo Nordisk A/S trades at $46.2 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares MSCI Australia ETF pays none, and iShares MSCI Australia ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

EWANVO
Sector
Broad Market / FactorHealth
52-Week High
$30.41$63.98
52-Week Low
$24.95$35.29
Market Cap
$207.85B
Enterprise Value
$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Australia ETF

EWA trades at $29.985, down 0.22% on the day, with a bullish technical signal from moving averages and strong trend strength indicated by ADX readings. The stock shows neutral momentum oscillators, and support/resistance levels are consolidated around $30. A dividend of $0.40 is scheduled for June 2026, providing income potential.

Outlook remains cautiously optimistic given technical strength, but fundamental data is unavailable for valuation assessment. Risks include reliance on Australian economic conditions and sector-specific headwinds. Investors should seek updated financials for a complete view amid mixed sentiment.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Australia ETF

EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.

Read more on EWA

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO